DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T. et al.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): A randomised phase 3 trial.
Lancet Oncol 2013;
14: 741-8
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.